Please try another search
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system. The company has collaboration agreement with the University of Kansas Cancer Center, as well as a research collaboration with Neoregen Biotech to develop novel NICT-delivered circVec therapeutic candidates. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Lysaker, Norway.
Name | Age | Since | Title |
---|---|---|---|
Damian Marron | 59 | 2020 | Chairman of the Board |
Diane Mary Mellett | 63 | 2015 | Independent Non-Executive Director |
Thomas Falck | 57 | 2022 | Director |
Robert Forbes Burns | 77 | 2015 | Independent Director |
Dean A. Fennell | - | 2020 | Member of Scientific Advisory Board |
Dmitriy Zamarin | - | 2020 | Member of Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review